New Probe Detects Fusion of bcr/abl

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 9
Volume 4
Issue 9

DOWNERS GROVE, Ill--Vysis Inc. has announced the availability of the Locus Specific Identifier (LSITM) bcr/abl translocation probe, a dual-color probe mixture that detects gene fusion of the bcr and abl genes.

DOWNERS GROVE, Ill--Vysis Inc. has announced the availabilityof the Locus Specific Identifier (LSITM) bcr/abl translocationprobe, a dual-color probe mixture that detects gene fusion ofthe bcr and abl genes.

This translocation has been associated with chronic myelogenousleukemia (CML) and acute lymphocytic leukemia (ALL).

The new probe, which is for research use only, is based on proprietaryapplications of FISH (fluorescence in situ hybridization) technology.The probe directly detects target DNA by hybridizing to specificlocations on individual chromosomes, the company said.

Bright Fluorescent Signal

Following hybridization, a bright fluorescent signal is emittedthat can be observed with use of a fluorescence microscope andimaging systems (see figure).

The LSI bcr/abl probe consists of a single probe for bcr (breakpointcluster region), directly labeled with the SpectrumGreenTM fluorochrome,and another probe for the Abelson oncogene (c-abl), directly labeledwith the Spec- trumOrangeTM fluorochrome.

The assay allows the user to quantitatively evaluate both probessimultaneously, either in interphase nuclei or metaphase cells.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content